Sosei Heptares doses first patient in trial for inflammatory bowel disease treatment
Betsy Goodfellow | March 21, 2024 | News story | Research and Development | Gastrointestinal tract, Sosei Heptares, clinical trial, inflammatory bowel disease, phase 1 trial
Sosei Heptares has announced that it has dosed the first patient in its phase 1 trial assessing a novel EP4 receptor agonist, HTL0033744 (HTL’744) for the treatment of inflammatory bowel disease (IBD).
According to the company’s press release, the candidate is ‘a potent, selective and gut-restricted prostaglandin EP4 receptor agonist that has been uniquely designed to bring clinical benefit by accelerating the healing of damaged epithelial mucosa and suppressing exaggerated gut inflammation, with minimal systemic exposure to avoid adverse events’.
It is intended that this candidate will address the unmet need of patients with IBD that do not achieve satisfactory disease control, as current standard-of-care treatments typically lead to remission rates of less than 25%.
The trial is a first-in-human randomised, double-blind study which will evaluate the safety, pharmacokinetics and effects on pharmacodynamic biomarkers of single and multiple ascending doses of the drug in health adult volunteers as well as patients with Crohn’s disease.
Matt Barnes, president of Heptares Therapeutic and head of UK R&D, commented: “It’s great to see the progression of HTL’744, another of our wholly owned assets, into the clinic. EP4 agonists are a recognised and exciting class of drugs with a dual mechanism of action that can resolve inflammation and promote mucosal healing. We’ve utilised our StaR/SBDD platform to develop a potent, selective and gut-restricted molecule that has potential to change the lives of the millions of people with IBD worldwide who are not benefitting from the currently available treatments.”
Betsy Goodfellow
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
